GuideView provides evidence of the efficacy of [18F]CTT1057 PET/CT as a molecular imaging biomarker for the detection of PSMA-positive lesions against histopathology in patients with PCa before initial curative therapy. Here, FOLH1 is linked to posterior cortical atrophy.